Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ABBV-668 ER
ABBV-668 · 1 trial · 1 indication
Endoscopic improvement was defined as Mayo endoscopic subscore of 0 or 1. The endoscopic subscore is scored from 0 (Normal appearance mucosa) to 3 (severe disease, spontaneous bleeding, ulceration) with lower scores associated with better health outcomes.
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
| Arm | Type | Description |
|---|---|---|
| ABBV-668 | EXPERIMENTAL | Participants will receive ABBV-668 twice daily approximately at same time each day for 16 weeks. |
| Name | Type | Description |
|---|---|---|
| ABBV-668 | DRUG | Oral Capsule |
Inclusion Criteria: * Diagnosis of ulcerative colitis (UC) for at least 90 days prior to Baseline. Appropriate documentation of biopsy results consistent with the diagnosis of UC in the assessment of the Investigator, must be available. * Participant meets the following disease activity criteria: A...
Top 20 of 23 competitors
ABBV-668 is an investigational oral small molecule developed by AbbVie Inc. for ulcerative colitis. It is also known as ABBV-668 ER. The drug has been studied in a Phase 2 clinical trial in adults with moderate to severe ulcerative colitis, and it has not been approved by the FDA.
ABBV-668 is being studied for the treatment of moderate to severe ulcerative colitis, a gastrointestinal inflammatory condition. The Phase 2 trial enrolled adults 18 years and older with this condition. ABBV-668 is investigational and has not been approved for any indication.
ABBV-668 is developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the clinical program evaluating the drug in ulcerative colitis.
ABBV-668 is in Phase 2 development. A single Phase 2 trial in moderate to severe ulcerative colitis has been completed, and no active trials are currently listed. The drug remains investigational and has not received FDA approval.
ABBV-668 has been evaluated in one completed Phase 2 trial, NCT05570006, titled a study of ABBV-668 oral capsules to assess adverse events and change in disease activity in adult participants with moderate to severe ulcerative colitis. The trial enrolled 30 participants across the United States, Belgium, France, and Poland.
Yes, ABBV-668 ER is an alternative name for ABBV-668. Both names refer to the same investigational oral small molecule developed by AbbVie Inc. for moderate to severe ulcerative colitis, so searches for either name refer to the same drug asset.